France To Fast-Track COVID-19 Clinical Trial Applications
Regulator Also Advises On Prioritizing Other Studies
Executive Summary
The continuing spread of the pandemic has led France to introduce accelerated procedures for approving clinical trials of therapies for patients infected by the coronavirus.
You may also be interested in...
EU Urges Sponsors To Assess COVID-19 Impact Before Starting New Trials
New EU guidance on managing clinical trials in the context of COVID-19 requires sponsors to critically assess the feasibility of starting a new clinical trial or including new participants in an ongoing trial. A separate survey indicates that patient willingness to participate in new trials has dramatically declined due to the pandemic.
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.